SRTS SEC Filing News — Sensus Healthcare, Inc.

Latest SEC filings for Sensus Healthcare, Inc. (SRTS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-31.

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as oth…
Sector: Healthcare Industry: Medical Devices Market Cap: $45.4M
20
Total Filings
9
Bullish Classifications
0
Bearish Classifications
10
Insider Transactions
7
Material Events (8-K)
3
Periodic Reports
Rule-based classifications for SRTS currently lean bullish. Of the 20 displayed SEC filing records, 9 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 10 insider transactions (Form 4) in this period.
SRTS Filing Activity Snapshot 2025-11-20 — 2026-08-31
Insider Transactions (Form 4)
9 buys vs 0 sells
Net insider buying in this period — more purchases than sales reported.
Largest Form 144 Filing
$225.6K
Sachetta Eric (Director) · 2026-08-31
64,841 shares · Form 4
Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for Sensus Healthcare, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 9 open-market purchase and 1 compensation award. 9 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×9
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Compensation award ×1
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Open-market purchase Insider Buying 2026-08-31

SRTS insider Sachetta Eric (Director) bought 64,841 shares (~$225.6K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 64,841 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 37,537 $3.44 $129.0K
P Open-market purchase 27,304 $3.54 $96.6K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 64,841 Est. Value: $225.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-08-28

SRTS insider Sachetta Eric (Director) bought 20,633 shares (~$66.7K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 20,633 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 9,708 $3.29 $31.9K
P Open-market purchase 10,925 $3.18 $34.8K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 20,633 Est. Value: $66.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-08-25

SRTS insider Sachetta Eric (Director) bought 34,697 shares (~$112.9K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 34,697 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 34,697 $3.25 $112.9K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 34,697 Est. Value: $112.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-08-24

SRTS insider Sardano Joseph C (Director, CHIEF EXECUTIVE OFFICER) bought 20,000 shares (~$60.5K)

Sardano Joseph C, listed as Director, CHIEF EXECUTIVE OFFICER at Sensus Healthcare, Inc., reported an open-market purchase of 20,000 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 20,000 $3.02 $60.5K
Filing: Form 4 (Insider Transaction) Insider: Sardano Joseph C (Director, CHIEF EXECUTIVE OFFICER) Shares: 20,000 Est. Value: $60.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-08-24

SRTS insider Sachetta Eric (Director) bought 31,000 shares (~$97.8K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 31,000 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 24,000 $3.13 $75.1K
P Open-market purchase 7,000 $3.25 $22.8K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 31,000 Est. Value: $97.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-05-12

SRTS insider Sachetta Eric (Director) bought 1,500 shares (~$5.0K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 1,500 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 1,500 $3.33 $5.0K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 1,500 Est. Value: $5.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-02-26

SRTS insider Sachetta Eric (Director) bought 2,000 shares (~$7.6K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 2,000 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 2,000 $3.81 $7.6K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 2,000 Est. Value: $7.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2025-12-16

SRTS insider Form 4 filed for equity award, exercise, or tax withholding

Sardano Michael (Director, PRESIDENT AND GENERAL COUNSEL) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 40,000 — —
Filing: Form 4 (Insider Transaction) Insider: Sardano Michael (Director, PRESIDENT AND GENERAL COUNSEL) Shares: 40,000
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2025-11-21

SRTS insider Sachetta Eric (Director) bought 7,000 shares (~$27.5K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 7,000 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 7,000 $3.93 $27.5K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 7,000 Est. Value: $27.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2025-11-20

SRTS insider Sachetta Eric (Director) bought 2,500 shares (~$11.2K)

Sachetta Eric, listed as Director at Sensus Healthcare, Inc., reported an open-market purchase of 2,500 SRTS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 2,500 $4.50 $11.2K
Filing: Form 4 (Insider Transaction) Insider: Sachetta Eric (Director) Shares: 2,500 Est. Value: $11.2K
View on SEC EDGAR → Open Filing Document →
Material Events 7 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 7 in this period for Sensus Healthcare, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-13

SRTS filed 8-K — material company event

Sensus Healthcare, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-05

SRTS filed 8-K — material company event

Sensus Healthcare, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-02

SRTS filed 8-K — material company event

Sensus Healthcare, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-07

SRTS filed 8-K — material company event

Sensus Healthcare, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-02-12

SRTS filed 8-K — material company event

Sensus Healthcare, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-01-20

SRTS filed 8-K — material company event

Sensus Healthcare, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-01-12

SRTS filed 8-K — material company event

Sensus Healthcare, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for Sensus Healthcare, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-14

SRTS filed Quarterly Report (10-Q)

Sensus Healthcare, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 10-Q Quarterly Report 2026-05-13

SRTS filed Quarterly Report (10-Q)

Sensus Healthcare, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 10-K Annual Report 2026-03-04

SRTS filed Annual Report (10-K)

Sensus Healthcare, Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)
View on SEC EDGAR → Open Filing Document →

How we classify Sensus Healthcare, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on SRTS. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — SRTS SEC Filings

More Tools for SRTS

SRTS Full Stock Analysis SRTS Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper SRTS analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the SRTS stock analysis page.

SRTS Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer